Proteasome Inhibition Enhances Lysosome-mediated Targeted Protein Degradation

This study demonstrates that combining proteasome inhibitors with an autophagy-targeting chimera (AUTAC) synergistically enhances lysosome-mediated degradation of the anti-apoptotic protein Mcl1 by exploiting the NRF1-driven adaptive autophagy response, thereby overcoming drug resistance and promoting cell death in multiple myeloma and lung cancer models.

The Gist

The Big Picture: A Cellular "Trash Day" Problem

Imagine your body's cells are like busy, high-tech factories. Inside these factories, there are two main ways to get rid of broken or unwanted machinery (proteins):

1. The Shredder (Proteasome): This is a powerful machine that chops up bad proteins into tiny pieces. It's the factory's primary waste disposal.
2. The Recycling Bin (Lysosome/Autophagy): This is a backup system that wraps up larger piles of trash and sends them to a recycling plant to be broken down.

The Current Treatment:
Doctors use drugs called Proteasome Inhibitors (like Carfilzomib) to treat blood cancers like Multiple Myeloma. Think of these drugs as putting a giant "STOP" sign on the Shredder. When the Shredder stops, the factory fills up with garbage. The pressure builds up, the factory gets stressed, and eventually, the cancer cell explodes (dies).

The Problem:
Cancer cells are sneaky survivors. When they see the Shredder stop, they panic and activate a "Plan B." They turn up the volume on the Recycling Bin (Autophagy). They start wrapping up the garbage and sending it to the recycling plant to clear the factory floor. This helps them survive the drug, leading to resistance and the cancer coming back.

The New Strategy: "Hijacking the Backup Plan"

Instead of trying to stop the Recycling Bin (which is hard and often hurts the patient), these researchers asked a clever question: What if we don't stop the recycling, but instead trick the cancer cell into recycling the one thing keeping it alive?

They created a new tool called an AUTAC (Autophagy-Targeting Chimera).

The AUTAC Analogy: The "GPS Sticker"
Imagine the cancer cell has a specific piece of machinery called Mcl1. Mcl1 is like the "Emergency Brake" for the cell; as long as Mcl1 is there, the cell refuses to die, even when the Shredder is broken.

The researchers built a two-part gadget:

1. The Magnet: One end of the gadget sticks specifically to Mcl1 (the Emergency Brake).
2. The GPS Tag: The other end is a special "Recycling Tag" (called FBnG) that tells the cell, "Hey, this belongs in the Recycling Bin!"

When the AUTAC attaches to Mcl1, it puts a giant "RECYCLE ME" sticker on the Emergency Brake. The cell's own recycling system grabs Mcl1 and destroys it. Without Mcl1, the Emergency Brake is gone, and the cell dies.

The "Power-Up" Combo

Here is the brilliant twist in the study:

The researchers found that when they combined the Proteasome Inhibitor (the Shredder blocker) with the AUTAC (the GPS sticker), the magic happened.

1. The Stress: The Proteasome Inhibitor stops the Shredder, causing the cell to panic and turn on its Recycling Bin (Autophagy) to survive.
2. The Trap: Because the cell is now super-active at recycling, the AUTAC's "Recycle Me" sticker on Mcl1 works ten times better. The cell is so eager to clean up its trash that it aggressively hunts down and destroys the Mcl1 Emergency Brake.
3. The Result: The cancer cell loses its Emergency Brake and its main trash disposal is broken. It collapses completely.

Why This is a Big Deal

1. Beating Resistance: This combo works even on cancer cells that have already learned to ignore the old drugs. The more the cancer tries to use its "Plan B" (recycling) to survive, the more it helps the new drug kill it.
2. Safety: Other drugs that try to stop Mcl1 often hurt the heart (cardiotoxicity) because they are too blunt. The AUTAC is like a sniper; it only targets Mcl1 when the cell is actively recycling, sparing the healthy heart cells.
3. The "NRF1" Factor: The study found that a specific protein called NRF1 acts as the manager that tells the cell to turn on the Recycling Bin when the Shredder is blocked. The new drug strategy relies on this manager doing its job, turning a survival mechanism into a death sentence for the cancer.

Summary in One Sentence

The researchers found a way to trick cancer cells into using their own "survival recycling system" to destroy their own "emergency brake," especially when they are already stressed by existing chemotherapy drugs, leading to a much more effective and safer cancer treatment.

Technical Summary

1. Problem Statement

• Clinical Limitation of Proteasome Inhibitors (PIs): While PIs (e.g., bortezomib, carfilzomib) are standard treatments for multiple myeloma and mantle cell lymphoma, their efficacy is limited in solid tumors and often compromised by acquired resistance.
• Mechanism of Resistance: Cancer cells counteract PI-induced proteotoxic stress by activating the transcription factor NRF1 (NFE2L1). NRF1 upregulates proteasome subunits and, crucially, induces cytoprotective autophagy. This adaptive autophagy allows tumor cells to clear protein aggregates and survive, leading to relapse.
• Targeting Mcl1: The anti-apoptotic protein Mcl1 is a key driver of PI resistance. While Mcl1 inhibitors exist, they often suffer from poor selectivity (affecting Bcl2/Bcl-xL) and severe cardiotoxicity.
• The Gap: Current strategies focus on inhibiting autophagy to sensitize cells to PIs. However, non-selective autophagy inhibitors (like chloroquine) have poor clinical utility due to toxicity and lack of specificity. There is a need for a strategy that leverages the heightened autophagic flux induced by PIs to selectively degrade resistance drivers like Mcl1.

2. Methodology

The authors employed a multi-faceted approach combining computational chemistry, molecular biology, and in vivo models:

• AUTAC Design & Computational Modeling:
  • Developed a second-generation Autophagy-Targeting Chimera (AUTAC) targeting Mcl1.
  • Structure: An Mcl1-binding warhead (S1-6 derivative) linked via a pyrazole linker to a fluorobenzyl guanine (FBnG) degradation tag.
  • Molecular Docking: Used Schrödinger's Glide and MM-GBSA to model binding to Mcl1, Bcl2, and Bcl-xL. Analyzed Solvent-Accessible Surface Area (SASA) to ensure the degradation tag remained exposed in Mcl1 but buried in Bcl2/Bcl-xL.
• In Vitro Validation:
  • Cell Lines: Multiple myeloma (U266B1, MM.1S, RPMI-8226, AMO-1) and Non-Small Cell Lung Cancer (NCI-H1975), including PI-resistant variants (U266B1R, NCI-H1975R).
  • Mechanistic Assays: Western blotting, Co-immunoprecipitation (Co-IP), and Immunofluorescence (IF) to track protein levels, ubiquitination (K63-linked), and autophagic flux (LC3B, p62, LAMP1).
  • Genetic/Pharmacological Perturbation: Used siRNA/shRNA to knock down key proteins (NRF1, p62/SQSTM1, TRAF6, UBC13, ATG5, Mcl1) and inhibitors (CQ, 3-MA, NAC, C25-140, NSC697923) to dissect the degradation pathway.
  • Synergy Testing: Combined AUTAC with Carfilzomib (CFZ) and calculated Bliss synergy scores.
• In Vivo Studies:
  • Xenograft Model: NSG mice injected with U266B1 cells. Treated with CFZ, AUTAC, or the combination.
  • Safety Profiling: Compared cytotoxicity of AUTAC against classical Mcl1 inhibitors (S63845, AMG 176, etc.) in human cardiomyocytes (AC16).

3. Key Contributions

1. Rational Design of Selective Mcl1 AUTAC: Demonstrated that structural topology at the BH3-binding groove periphery allows for selective degradation of Mcl1 over Bcl2/Bcl-xL, avoiding off-target effects.
2. Elucidation of the Degradation Mechanism: Defined the specific molecular pathway: AUTAC induces K63-linked ubiquitination of Mcl1 via the TRAF6/UBC13 E3/E2 ligase axis. This tag is recognized by the cargo receptor p62/SQSTM1, which delivers Mcl1 to the lysosome for degradation.
3. Paradigm Shift in Autophagy Modulation: Instead of inhibiting the adaptive autophagy response to PIs, the study shows that proteasome inhibition (via CFZ) amplifies AUTAC efficacy. CFZ induces NRF1-dependent autophagy, which the AUTAC hijacks to clear Mcl1 more efficiently.
4. Overcoming Resistance: Showed that the combination of CFZ and AUTAC synergistically kills PI-resistant cancer cells by degrading Mcl1, a primary mechanism of resistance.

4. Key Results

• Selectivity: The AUTAC degraded Mcl1 in a dose- and time-dependent manner without affecting Bcl2 or Bcl-xL. Molecular docking confirmed that the FBnG tag is solvent-exposed in Mcl1 complexes but sterically hindered in Bcl2/Bcl-xL.
• Autophagy Dependence: Mcl1 degradation was blocked by autophagy inhibitors (CQ, 3-MA) and genetic knockdown of ATG5 or p62, confirming lysosomal degradation.
• Mechanism of Action:
  • AUTAC treatment increased K63-linked ubiquitination of Mcl1.
  • Co-IP and IF confirmed colocalization of Mcl1 with K63-Ub, p62, and LC3B.
  • Inhibition of TRAF6 or UBC13 abolished Mcl1 degradation and cell death, proving their essential role.
  • AUTAC induced autophagy via Beclin1 activation (by disrupting Mcl1-Beclin1 binding), not via mTOR suppression or ROS generation.
• Synergy with Proteasome Inhibitors:
  • CFZ treatment upregulated NRF1, p62, and autophagy genes.
  • NRF1 Knockout abolished CFZ-induced autophagy and prevented the synergistic degradation of Mcl1 by the CFZ+AUTAC combination.
  • The combination significantly reduced cell viability and induced apoptosis (cleaved caspase 3/PARP) in both wild-type and PI-resistant myeloma and lung cancer cells.
• In Vivo Efficacy: In U266B1 xenografts, the CFZ + AUTAC combination resulted in significantly smaller tumor volumes compared to monotherapies, with no observed toxicity (body weight stability).
• Safety Profile: Unlike classical Mcl1 inhibitors (e.g., S63845, AMG 176) which were highly toxic to cardiomyocytes (AC16), the AUTAC showed no detectable cardiotoxicity at effective concentrations.

5. Significance

• Novel Therapeutic Strategy: This study establishes a "leveraging" strategy where the adaptive resistance mechanism (autophagy) induced by standard-of-care drugs (PIs) is repurposed to enhance the degradation of resistance drivers.
• Solution to Mcl1 Targeting: It offers a potential solution to the cardiotoxicity and selectivity issues plaguing current Mcl1 inhibitors by using a targeted degradation approach rather than simple inhibition.
• Broad Applicability: The framework of combining PIs with AUTACs to amplify lysosomal degradation could be extended to other resistance-associated proteins and solid tumors where PIs have historically failed.
• Clinical Potential: The combination of an FDA-approved PI (Carfilzomib) with a novel AUTAC provides a promising, low-toxicity avenue for treating relapsed/refractory multiple myeloma and potentially solid tumors.